TNF-α inhibitors such as adalimumab, etanercept, and infliximab—are among the most commonly used bDMARDs and have demonstrated efficacy in reducing disease activity and improving quality of life in patients with RA (Singh et al. 2009; Ben Mrid et al. 2022). Here, TNF is linked to rheumatoid arthritis.